Goldman Sachs Starts Regeneron Pharma (REGN) at Buy, Sees 23% Upside

Article Stock Quotes (1) Comments (0)

Goldman Sachs initiates coverage on Regeneron Pharma (NASDAQ: REGN) with a Buy and $144 price target, suggesting 23% upside. The firm said Eylea is on its way to blockbuster status.

"The key driver for shares is recently launched drug, Eylea, for a variety of eye diseases that lead to vision loss," the analyst said. "We anticipate continued robust uptake of Eylea (GS WW peak sales of $4bn, $2.3bn in US), which we project will propel the company to sustainable profitability in 4Q12."

For an analyst ratings summary and ratings history on Regeneron Pharma click here. For more ratings news on Regeneron Pharma click here.

Shares of Regeneron Pharma closed at $116.62 yesterday, with a 52 week range of $41.83-$121.39.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• Deutsche Bank Starts Alnylam Pharmaceuticals (ALNY) at Buy
• Topeka Capital Starts RDA Microelectronics (RDA) at Buy
• Topeka Capital Starts CEVA Inc. (CEVA) at Buy

Create E-mail Alert Related Categories

Hot New Coverage, New Coverage

Related Entities

Goldman Sachs

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?